Announcements
- Junshi Biosciences Announces NDA Acceptance in Hong Kong for Toripalimab
- Junshi Biosciences Announces Approval of the sNDA for Toripalimab for the 1st-Line Treatment of Renal Cancer
- Junshi Biosciences Announces 2023 Full Year Financial Results and Provides Corporate Updates
- Junshi Biosciences Announces Toripalimab’s NDA Accepted by the Singapore Health Sciences Authority
- Junshi Biosciences Announces JAMA Publication of Results from NEOTORCH, a Randomized Phase 3 Trial of Perioperative Toripalimab plus Chemotherapy for Patients with Resectable Non-Small Cell Lung Cancer
- Junshi Biosciences Announces Publication of Results from TORCHLIGHT, a Randomized Phase 3 Trial of Toripalimab for the Treatment of Metastatic or Recurrent Triple-negative Breast Cancer in Nature Medicine
- Junshi Biosciences Announces Approval of the Supplemental New Drug Application for Toripalimab as Perioperative Treatment for Resectable NSCLC Patients
- Junshi Biosciences Announces New Chemical Entity Application for Toripalimab Accepted by Australia’s TGA
- Junshi Biosciences Announces Lancet Infectious Diseases Publication of Results from the 2nd Phase 3 Study of VV116 for Treating COVID-19
- Junshi Biosciences Presents 11 Clinical Trials of Toripalimab at the ESMO Congress 2023
More ▼
Key statistics
On Friday, Shanghai Junshi Biosciences Co Ltd (8SJ:FRA) closed at 1.41, 33.02% above the 52 week low of 1.06 set on Apr 19, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.37 |
---|---|
High | 1.45 |
Low | 1.37 |
Bid | 1.39 |
Offer | 1.52 |
Previous close | 1.30 |
Average volume | 2.04k |
---|---|
Shares outstanding | 985.69m |
Free float | 150.24m |
P/E (TTM) | -- |
Market cap | 24.95bn HKD |
EPS (TTM) | -2.50 HKD |
Data delayed at least 15 minutes, as of May 31 2024 08:59 BST.
More ▼